Johnson & Johnson (JNJ)
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General